Youming Wang , Weibing Jia , Minjia Wang , Xiaoli Yang , Xinli Gao , Yao Zhang
{"title":"癌症患者的渗透性脱髓鞘综合征:即使没有快速钠纠正也有风险-一项范围审查","authors":"Youming Wang , Weibing Jia , Minjia Wang , Xiaoli Yang , Xinli Gao , Yao Zhang","doi":"10.1016/j.jns.2024.123326","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To describe the clinical characteristics, therapeutic approaches, and prognostic outcomes of osmotic demyelination syndrome (ODS) in cancer patients.</div></div><div><h3>Methods</h3><div>A comprehensive literature search (January 1950–March 2024) using PubMed, Embase, Cochrane Library, and Web of Science. Keywords included “osmotic demyelination and cancer”, “central pontine myelinolysis and cancer”, and “extrapontine myelinolysis and cancer”, “Osmotic demyelination and malignancy,” “Central pontine myelinolysis and malignancy,” and “Extrapontine myelinolysis and malignancy.” References from selected articles were manually reviewed for inclusion. Studies involving benign lesions, surgical interventions, non-malignant ODS, and ODS of unknown etiology without malignancy were excluded.</div></div><div><h3>Results</h3><div>A total of 22 cases of cancer-complicated ODS were identified in the literature. The median age of onset was 55 years, with no observed gender differences. Clinical presentations ranged from completely asymptomatic (4.5 %,1/22) to disorders of consciousness (27.3 %, 6/22). Notably, 22.7 % (5/22) of patients initially presented with either no symptoms or non-specific symptoms (seizures, abnormal mental behavior) that could be mistaken for hyponatremia itself. Furthermore, 90 % of patients did not experience rapid sodium correction, and 59.1 % received only symptomatic therapy or treatment of the primary cancer. Only 9.1 % of patients received immunoglobulin or plasma exchange, which may improve outcomes.</div></div><div><h3>Conclusions</h3><div>Osmotic demyelination syndrome represents a potential complication in cancer patients, potentially arising from complex interactions. Clinical manifestations are highly variable and often under-recognized, particularly by non-neurologists. Traditional sodium correction protocols may still induce ODS in cancer patients, suggesting a need for cautious sodium management. Timely diagnosis and appropriate intervention are crucial for determining patient prognosis.</div></div>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"467 ","pages":"Article 123326"},"PeriodicalIF":3.6000,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Osmotic demyelination syndrome in cancer patients: Risk even without rapid sodium correction - a scoping review\",\"authors\":\"Youming Wang , Weibing Jia , Minjia Wang , Xiaoli Yang , Xinli Gao , Yao Zhang\",\"doi\":\"10.1016/j.jns.2024.123326\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>To describe the clinical characteristics, therapeutic approaches, and prognostic outcomes of osmotic demyelination syndrome (ODS) in cancer patients.</div></div><div><h3>Methods</h3><div>A comprehensive literature search (January 1950–March 2024) using PubMed, Embase, Cochrane Library, and Web of Science. Keywords included “osmotic demyelination and cancer”, “central pontine myelinolysis and cancer”, and “extrapontine myelinolysis and cancer”, “Osmotic demyelination and malignancy,” “Central pontine myelinolysis and malignancy,” and “Extrapontine myelinolysis and malignancy.” References from selected articles were manually reviewed for inclusion. Studies involving benign lesions, surgical interventions, non-malignant ODS, and ODS of unknown etiology without malignancy were excluded.</div></div><div><h3>Results</h3><div>A total of 22 cases of cancer-complicated ODS were identified in the literature. The median age of onset was 55 years, with no observed gender differences. Clinical presentations ranged from completely asymptomatic (4.5 %,1/22) to disorders of consciousness (27.3 %, 6/22). Notably, 22.7 % (5/22) of patients initially presented with either no symptoms or non-specific symptoms (seizures, abnormal mental behavior) that could be mistaken for hyponatremia itself. Furthermore, 90 % of patients did not experience rapid sodium correction, and 59.1 % received only symptomatic therapy or treatment of the primary cancer. Only 9.1 % of patients received immunoglobulin or plasma exchange, which may improve outcomes.</div></div><div><h3>Conclusions</h3><div>Osmotic demyelination syndrome represents a potential complication in cancer patients, potentially arising from complex interactions. Clinical manifestations are highly variable and often under-recognized, particularly by non-neurologists. Traditional sodium correction protocols may still induce ODS in cancer patients, suggesting a need for cautious sodium management. Timely diagnosis and appropriate intervention are crucial for determining patient prognosis.</div></div>\",\"PeriodicalId\":17417,\"journal\":{\"name\":\"Journal of the Neurological Sciences\",\"volume\":\"467 \",\"pages\":\"Article 123326\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2024-11-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Neurological Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0022510X24004623\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Neurological Sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0022510X24004623","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的探讨肿瘤患者渗透性脱髓鞘综合征(ODS)的临床特点、治疗方法及预后。方法利用PubMed、Embase、Cochrane Library和Web of Science进行文献检索(1950年1月~ 2024年3月)。关键词包括“渗透性脱髓鞘与癌症”、“桥桥中央髓鞘溶解与癌症”、“桥桥外髓鞘溶解与癌症”、“渗透性脱髓鞘与恶性肿瘤”、“桥桥中央髓鞘溶解与恶性肿瘤”、“桥桥外髓鞘溶解与恶性肿瘤”。对选定文章的参考文献进行了人工审查以纳入。包括良性病变、手术干预、非恶性ODS和病因不明的无恶性ODS的研究被排除在外。结果文献共发现22例肿瘤合并ODS。中位发病年龄为55岁,没有观察到性别差异。临床表现从完全无症状(4.5%,1/22)到意识障碍(27.3%,6/22)不等。值得注意的是,22.7%(5/22)的患者最初表现为无症状或非特异性症状(癫痫发作、异常精神行为),这些症状可能被误认为低钠血症本身。此外,90%的患者没有经历快速的钠矫正,59.1%的患者只接受了对症治疗或原发癌症的治疗。只有9.1%的患者接受了免疫球蛋白或血浆交换,这可能会改善预后。结论渗透性脱髓鞘综合征是肿瘤患者的一种潜在并发症,可能由复杂的相互作用引起。临床表现是高度可变的,经常被忽视,特别是非神经科医生。传统的钠校正方案仍可能诱发癌症患者的ODS,提示需要谨慎的钠管理。及时诊断和适当干预是确定患者预后的关键。
Osmotic demyelination syndrome in cancer patients: Risk even without rapid sodium correction - a scoping review
Objective
To describe the clinical characteristics, therapeutic approaches, and prognostic outcomes of osmotic demyelination syndrome (ODS) in cancer patients.
Methods
A comprehensive literature search (January 1950–March 2024) using PubMed, Embase, Cochrane Library, and Web of Science. Keywords included “osmotic demyelination and cancer”, “central pontine myelinolysis and cancer”, and “extrapontine myelinolysis and cancer”, “Osmotic demyelination and malignancy,” “Central pontine myelinolysis and malignancy,” and “Extrapontine myelinolysis and malignancy.” References from selected articles were manually reviewed for inclusion. Studies involving benign lesions, surgical interventions, non-malignant ODS, and ODS of unknown etiology without malignancy were excluded.
Results
A total of 22 cases of cancer-complicated ODS were identified in the literature. The median age of onset was 55 years, with no observed gender differences. Clinical presentations ranged from completely asymptomatic (4.5 %,1/22) to disorders of consciousness (27.3 %, 6/22). Notably, 22.7 % (5/22) of patients initially presented with either no symptoms or non-specific symptoms (seizures, abnormal mental behavior) that could be mistaken for hyponatremia itself. Furthermore, 90 % of patients did not experience rapid sodium correction, and 59.1 % received only symptomatic therapy or treatment of the primary cancer. Only 9.1 % of patients received immunoglobulin or plasma exchange, which may improve outcomes.
Conclusions
Osmotic demyelination syndrome represents a potential complication in cancer patients, potentially arising from complex interactions. Clinical manifestations are highly variable and often under-recognized, particularly by non-neurologists. Traditional sodium correction protocols may still induce ODS in cancer patients, suggesting a need for cautious sodium management. Timely diagnosis and appropriate intervention are crucial for determining patient prognosis.
期刊介绍:
The Journal of the Neurological Sciences provides a medium for the prompt publication of original articles in neurology and neuroscience from around the world. JNS places special emphasis on articles that: 1) provide guidance to clinicians around the world (Best Practices, Global Neurology); 2) report cutting-edge science related to neurology (Basic and Translational Sciences); 3) educate readers about relevant and practical clinical outcomes in neurology (Outcomes Research); and 4) summarize or editorialize the current state of the literature (Reviews, Commentaries, and Editorials).
JNS accepts most types of manuscripts for consideration including original research papers, short communications, reviews, book reviews, letters to the Editor, opinions and editorials. Topics considered will be from neurology-related fields that are of interest to practicing physicians around the world. Examples include neuromuscular diseases, demyelination, atrophies, dementia, neoplasms, infections, epilepsies, disturbances of consciousness, stroke and cerebral circulation, growth and development, plasticity and intermediary metabolism.